ADAR1 Capital Management LLC Acquires 112,339 Shares of Lexeo Therapeutics, Inc. (NASDAQ:LXEO)

ADAR1 Capital Management LLC increased its stake in shares of Lexeo Therapeutics, Inc. (NASDAQ:LXEO - Free Report) by 196.5% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 169,505 shares of the company's stock after purchasing an additional 112,339 shares during the period. ADAR1 Capital Management LLC owned approximately 0.51% of Lexeo Therapeutics worth $1,115,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in LXEO. Frazier Life Sciences Management L.P. purchased a new stake in Lexeo Therapeutics during the 3rd quarter valued at $11,307,000. Geode Capital Management LLC grew its holdings in shares of Lexeo Therapeutics by 2.6% in the fourth quarter. Geode Capital Management LLC now owns 567,383 shares of the company's stock worth $3,735,000 after acquiring an additional 14,136 shares during the period. Point72 Asset Management L.P. purchased a new stake in Lexeo Therapeutics during the third quarter valued at $3,348,000. State Street Corp lifted its holdings in Lexeo Therapeutics by 29.4% in the third quarter. State Street Corp now owns 253,946 shares of the company's stock valued at $2,296,000 after acquiring an additional 57,674 shares during the period. Finally, Privium Fund Management B.V. bought a new stake in shares of Lexeo Therapeutics during the 4th quarter valued at about $909,000. Institutional investors own 60.67% of the company's stock.

Analysts Set New Price Targets

LXEO has been the subject of several recent research reports. Leerink Partners cut their target price on shares of Lexeo Therapeutics from $19.00 to $18.00 and set an "outperform" rating for the company in a research report on Monday, March 24th. HC Wainwright restated a "buy" rating and issued a $23.00 price objective on shares of Lexeo Therapeutics in a research note on Tuesday. Royal Bank of Canada lowered their target price on Lexeo Therapeutics from $24.00 to $20.00 and set an "outperform" rating on the stock in a research report on Tuesday, March 25th. Finally, Chardan Capital lowered their price objective on Lexeo Therapeutics from $25.00 to $22.00 and set a "buy" rating on the stock in a research report on Tuesday. Five analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of "Buy" and an average target price of $22.20.

Remove Ads

Lexeo Therapeutics Price Performance

LXEO traded down $0.19 during trading on Friday, reaching $1.98. 864,163 shares of the company traded hands, compared to its average volume of 400,511. The company has a market cap of $65.73 million, a P/E ratio of -0.63 and a beta of 1.52. The company has a debt-to-equity ratio of 0.01, a quick ratio of 5.95 and a current ratio of 5.95. Lexeo Therapeutics, Inc. has a 12-month low of $1.45 and a 12-month high of $19.50. The firm has a fifty day simple moving average of $3.33 and a 200 day simple moving average of $5.97.

Lexeo Therapeutics (NASDAQ:LXEO - Get Free Report) last announced its quarterly earnings results on Monday, March 24th. The company reported ($0.78) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.87) by $0.09. On average, equities analysts forecast that Lexeo Therapeutics, Inc. will post -3.14 EPS for the current year.

Lexeo Therapeutics Profile

Lexeo Therapeutics, Inc operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene.